Rupa Parvataneni

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Identifying the needs of brain tumor patients and their caregivers
    Rupa Parvataneni
    Division of Neuro Oncology in the Department of Neurosurgery, University of California, San Francisco, CA 94143, USA
    J Neurooncol 104:737-44. 2011
  2. ncbi Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 13:1331-8. 2011
  3. ncbi Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging
    Ramon F Barajas
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158 2330, USA
    Neuro Oncol 14:942-54. 2012
  4. ncbi Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    Michael D Prados
    University of California, San Francisco, CA 94143, USA
    J Clin Oncol 27:579-84. 2009
  5. ncbi Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas
    Adam Elkhaled
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94158, USA
    Sci Transl Med 4:116ra5. 2012

Collaborators

Detail Information

Publications5

  1. ncbi Identifying the needs of brain tumor patients and their caregivers
    Rupa Parvataneni
    Division of Neuro Oncology in the Department of Neurosurgery, University of California, San Francisco, CA 94143, USA
    J Neurooncol 104:737-44. 2011
    ....
  2. ncbi Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 13:1331-8. 2011
    ..Adjusting for age and KPS, no other biomarker was associated with survival outcome. Correlation of relevant biomarkers with OS may be useful in future trials...
  3. ncbi Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging
    Ramon F Barajas
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158 2330, USA
    Neuro Oncol 14:942-54. 2012
    ..Image-guided tissue acquisition and assessment of residual tumor from treatment-naive GBM should be guided by DSC in CE regions and by DWI in NE regions...
  4. ncbi Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    Michael D Prados
    University of California, San Francisco, CA 94143, USA
    J Clin Oncol 27:579-84. 2009
    ..The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response...
  5. ncbi Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas
    Adam Elkhaled
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94158, USA
    Sci Transl Med 4:116ra5. 2012
    ..Such information may augment the ability of clinicians to monitor therapeutic response and provide criteria for stratifying patients to specific treatment regimens...